Sulfachloropyridazine sodium is a sulfonamide antibiotic used to study kinetics and reaction pathways. Also, it is used to treat acute Urinary Tract Infections (UTIs) in pediatric patients. Sulfachloropyridazine sodium blocks the synthesis of dihydrofolic acid by inhibiting the enzyme dihydropteroate synthase and bacterial Para-Amino Benzoic Acid (PABA), which is required for bacterial growth. The compound Sulfachloropyridazine sodium powder has a curative effect for various animals with pasteurellosis and is popular for use in animal husbandry.
Rising use of antibiotics in animals to treat certain infections is expected to drive growth of the sulfachloropyridazine sodium market. For instance, according to an article published in journal Science, 2017, almost 80% of all antibiotics in the U.S. are administered to cows, pigs, and chickens to keep them healthy and accelerate their growth and development.
Moreover, according to the Louisiana Department of Health, U.S., due to low cost and relatively better efficacy against many common bacterial infections, sulfonamides are some of the most common antibacterial agents utilized in veterinary medicine, which is in turn is boosting growth of the sulfachloropyridazine sodium market.
Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/2263
Over the years, bacterial pathogens have acquired resistance to sulfonamide class of antibiotics, due to mutations in pre-existing DNA or by acquisition of Antibiotic Resistance Genes (ARGs), which is expected to hinder growth of the sulfachloropyridazine sodium market. For instance, according to an article published in journal Microbiome, 2017, use of sulfonamide class of antibiotics is restricted to topical use only extensively for animals. For instance, in the U.S., around 380,186 kg of sulfonamides was distributed legally during 2015, to increase the resistance power of food-producing animals. Hence, further spread of sulfonamide resistance would have hamper the market particularly in the animal sector.
On the basis of region, the global sulfachloropyridazine sodium market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America region is expected to gain maximum share in the sulfachloropyridazine sodium market, owing to high prevalence of Urinary Tract Infections (UTIs) in the U.S. For instance, according to American Urological Association 2016, more than 1 million catheter-associated UTIs are reported annually in the U.S. and up to 40% of hospital gram negative bacteremias originate as UTIs annually, which are treated by antibiotics.
Asia Pacific region is expected to witness significant growth in the sulfachloropyridazine market due to involvement of key players in manufacturing antibiotics solely for veterinary purposes. One of the company named Weifang Premier Animal Pharmaceutical Industries Co., Ltd, a China-based company also involved in animal husbandry. They contributes to animal health by manufacturing sulfachloropyridazine sodium soluble powder as one of the key product in China.
Key players involved in Sulfachloropyridazine market include Sigma-Aldrich, Inc., Zhengzhou Fuyuan Chemical Industry Co., Ltd, Santa Cruz Biotechnology, Inc., UBM, Hefei TNJ Chemical Industry Co., Ltd., AK Scientific Inc., SuZhou Wugan Pharmaceutical Co., Quimica Alkano, Shanghai Danfan Network Science&Technology Co., Ltd., and Ofichem Group.
Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2263
Sulfachloropyridazine Sodium Market – Taxonomy
By Patient Type
- North America
- Asia Pacific
- Latin America
- Middle East
Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2263